Ken Griffin Viracta Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$0.5 - $1.17 $2,500 - $5,850	5,000 Added 84.75%	10,900 $5,000
Q1 2024 May 15, 2024	BUY	$0.48 - $1.13 $2,304 - $5,423	4,800 Added 436.36%	5,900 $6,000
Q4 2023 Feb 14, 2024	SELL	$0.44 - $1.04 $132 - $312	-300 Reduced 21.43%	1,100 $0
Q3 2023 Nov 14, 2023	SELL	$1.03 - $1.58 $1,442 - $2,212	-1,400 Reduced 50.0%	1,400 $1,000
Q2 2023 Aug 14, 2023	BUY	$0.89 - $2.13 $1,958 - $4,686	2,200 Added 366.67%	2,800 $3,000
Q1 2023 May 15, 2023	SELL	$1.38 - $2.29 $29,173 - $48,410	-21,140 Reduced 97.24%	600 $0
Q4 2022 Feb 14, 2023	SELL	$1.26 - $4.38 $56,322 - $195,786	-44,700 Reduced 67.28%	21,740 $31,000
Q3 2022 Nov 14, 2022	SELL	$3.32 - $5.69 $65,404 - $112,093	-19,700 Reduced 22.87%	66,440 $284,000

9.04M

10.9K

400

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $7.51M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.